This study describes the safety and efficacy of amphotericin B lipid comple
x (ABLC) in 11 neonates with systemic Candida infections. Nine of the 11 im
proved clinically, and eight of nine evaluable patients had a mycological c
ure with ABLC. Creatinine levels improved or did not significantly change i
n eight of the 11 patients.